Business Context and Reporting Period
Company: Sintx Technologies, Inc. (SINT)
Filing Type: Form 8-K (Current Report)
Date of Report: June 29, 2026
Principal Executive Offices: Salt Lake City, UT
The filing reports the execution of a Letter Agreement with MedTech Ceramics, LP to restructure equity instruments held in abeyance and existing warrants. The transaction is part of the Company's ongoing efforts to manage its capital structure and address the balance sheet treatment of specific shares.
Key Financial Metrics
This filing does not contain standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on a specific capital structure transaction.
Material Changes and Transaction Details
On June 29, 2026, the Company finalized an agreement with MedTech Ceramics, LP involving the following changes to equity instruments:
- Release of Shares: The Company will issue 255,267 shares of Common Stock from abeyance to the Holder for no additional consideration.
- Pre-Funded Warrant: The remaining 251,987 abeyance shares will be replaced by a Pre-Funded Warrant covering the same number of shares. This warrant has no fixed expiration date and is exercisable via a cashless mechanism.
- Warrant Replacement: The Holder's existing warrant (September 2025) to purchase 760,881 shares was cancelled and replaced with a New Warrant to purchase 1,268,135 shares at an exercise price of $2.14 per share.
- Registration: The Company agreed to file a resale registration statement for the New Warrant shares within 45 days.
Outlook, Risks, and Management Commentary
Management Commentary: The Company expects these transactions to support efforts to improve its stockholders' equity position. However, management notes that the equity position will continue to depend on the Company's overall financial condition and results of operations.
Terms and Risks:
- Anti-Dilution: The New Warrant is subject to a full-ratchet downward adjustment in any dilutive equity financing, subject to stockholder approval as required by Nasdaq Listing Rule 5635(d).
- Ownership Limitations: Both the Pre-Funded Warrant and the New Warrant are subject to a 9.99% beneficial ownership limitation.
- Expiration: The New Warrant expires five years from the date of issuance.
Investor Verification Checklist
- Verify the impact of the 255,267 released shares on the Company's current share count and potential dilution.
- Review the full text of the Letter Agreement (Exhibit 10.1) and warrant forms (Exhibits 4.1 and 4.2) for specific covenants.
- Monitor the filing of the resale registration statement for the New Warrant, which is due within 45 days of June 29, 2026.
- Assess the risk of the full-ratchet anti-dilution provision on the New Warrant in the event of future equity financings.
- Confirm the Company's current stockholders' equity position in the most recent 10-Q or 10-K to contextualize the stated goal of improving equity.